About Modunai Therapeutics

Pioneering Stress-Adaptation Biology to Overcome Therapy Resistance.

Modunai Therapeutics is advancing a new class of AI-engineered antibody medicines that eliminate residual and resistant disease in cancer and autoimmunity. Leveraging the emerging field of stress-adaptation biology, we design bispecific and pH-selective antibody-drug conjugate (ADC) therapeutics that precisely target key biological drivers of therapy escape.

🌍 Mission & Vision

Advancing precision biologics that turn therapy resistance into vulnerability and relapse into remission—delivering durable cures for cancer and immune-mediated diseases.

👩‍🔬 Founding Team

Founded by entrepreneurs and scientists with deep expertise in bispecific and ADC discovery, immunology, and translational science, Modunai’s team has advanced programs from concept to clinic, united by a mission to transform stress-adaptation biology into novel therapeutics for unmet needs.